Dalia A. Elmehy

Dalia A. Elmehy

Auto-generated profile, based on publicly available information

Dalia A. Elmehy

Medical Parasitology Department, Faculty of Medicine, Tanta University, Tanta, Egypt

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 May 2021 in Parasitology Research
Verified
Journal Article
Closed access
PDF file
DEDalia A. Elmehy
Dalia A. Elmehy
MSMarwa A. Hasby Saad
Marwa A. Hasby Saad
GMGamal M. El Maghraby
Gamal M. El Maghraby
MAMona F. Arafa
Mona F. Arafa
NSNema A. Soliman
Nema A. Soliman
DEDina I. Elgendy
Dina I. Elgendy

14 February 2023 in Parasitology Research
Verified
Journal Article
Open access
PDF file
TATasneem M. Almallah
Tasneem M. Almallah
SKSafaa I. Khedr
Safaa I. Khedr
KNKholoud A. El Nouby
Kholoud A. El Nouby
SYSalwa Sami Younis
Salwa Sami Younis
MEMona A. Elazeem
Mona A. Elazeem
DEDalia A. Elmehy
Dalia A. Elmehy
Toxoplasmosis is an immunologically complex disease, particularly in immunocompromised patients. Although there are several therapeutic regimens for such disease, the majority of them have many drawbacks. Therefore, it is of utmost importance to improve the current regimen in an effort to achieve a well-tolerated therapy while also enhancing the host immune response. Famous for their immunomodulatory effect, Lactobacillus delbrueckii and Lactobacillus fermentum probiotics were chosen to be evaluated in this study as an adjuvant therapy against the virulent RH Toxoplasma gondii (T. gondii) strain. Experimental mice were divided into control and treated groups. The control group was further subdivided into two groups: group I: 10 uninfected mice and group II: 20 infected untreated mice. The treated experimental group was subdivided into three groups (20 mice each); group III: sulfamethoxazole-trimethoprim (SMZ-TMP) treated, group IV: probiotics treated, and group V: SMZ-TMP combined with probiotics. The results obtained revealed that combined therapy increased survival rate and time up to 95% and 16 days, respectively, with an 82% reduction of tachyzoites and marked distortion, as detected by the scanning electron microscope (SEM). Additionally, combined therapy alleviated the severity and the extent of the inflammatory cells’ infiltration, thereby reducing hepatocyte degeneration. Intriguingly, serum IF-γ level showed a significant increase to 155.92 ± 10.12 ng/L with combined therapy, reflecting the immunological role of the combined therapy. The current results revealed that probiotics have a high adjuvant potential in alleviating the impact of toxoplasmosis. Using probiotics as a synergistic treatment to modulate conventional therapy in systemic toxoplasmosis may gain popularity due to their low cost and current availability.

1 August 2021 in Acta Tropica
Verified
Journal Article
Closed access
DEDalia A Elmehy
Dalia A Elmehy
DADina I Abdelhai
Dina I Abdelhai
RERasha A Elkholy
Rasha A Elkholy
MEMaram M Elkelany
Maram M Elkelany
DTDina M Tahoon
Dina M Tahoon
GGGhada A Gamea
Ghada A Gamea

1 January 2021 in Acta Tropica
Verified
Journal Article
Closed access
DEDalia A. Elmehy
Dalia A. Elmehy
HIHowaida I.H. Ismail
Howaida I.H. Ismail
NSNema A. Soliman
Nema A. Soliman
BABasma S. Amer
Basma S. Amer
HEHeba H. Elkaliny
Heba H. Elkaliny
GGGhada A. Gamea
Ghada A. Gamea

17 August 2018 in Parasite Immunology
Verified
Journal Article
Closed access
PDF file
MSMarwa A. Hasby Saad
Marwa A. Hasby Saad
MWMona Watany
Mona Watany
MTMohamed Tomoum
Mohamed Tomoum
DEDalia El‐Mehy
Dalia El‐Mehy
MEMay R. Elsheikh
May R. Elsheikh
RSRagia Sharshar
Ragia Sharshar

7 May 2024 in Parasite Immunology
Verified
Journal Article
Closed access
SYSalwa S. Younis
Salwa S. Younis
ASAmina M. Salama
Amina M. Salama
DEDalia A. Elmehy
Dalia A. Elmehy
NHNehal A. Heabah
Nehal A. Heabah
HRHanem M. Rabah
Hanem M. Rabah
GGGhada A. Gamea
Ghada A. Gamea